We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-2.77%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.85B
AUM Growth
+$375M
Cap. Flow
-$1.26B
Cap. Flow %
-25.93%
Top 10 Hldgs %
37.89%
Holding
140
New
14
Increased
21
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$50.2M
2
GILD icon
Gilead Sciences
GILD
+$48.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$32.8M
4
MRUS
Merus
MRUS
+$32.3M
5
GKOS icon
Glaukos
GKOS
+$31.8M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$25.7M
2
ORGO icon
Organogenesis Holdings
ORGO
+$24.7M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$22.2M
4
GDRX icon
GoodRx Holdings
GDRX
+$18.9M
5
NUVB icon
Nuvation Bio
NUVB
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 51.31%
2 Financials 1.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EUCR
51
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$9.9M 0.2%
999,999
– –
SRSA
52
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$9.89M 0.2%
999,999
– –
TLSI icon
53
TriSalus Life Sciences
TLSI
$262M
$9.85M 0.2%
999,999
– –
SNRH
54
DELISTED
Senior Connect Acquisition Corp. I Class A Common Stock
SNRH
$9.84M 0.2%
1,000,000
– –
REVH
55
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
$9.77M 0.2%
1,000,000
– –
PEPG icon
56
PepGen
PEPG
$156M
$9.47M 0.2%
+953,626
New +$10.6M
TMPM
57
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$7.45M 0.15%
750,000
– –
NKTX icon
58
Nkarta
NKTX
$187M
$7.39M 0.15%
+600,000
New +$7.87M
PKBO
59
DELISTED
Peak Bio, Inc. Common Stock
PKBO
$7.15M 0.15%
725,000
– –
APEN
60
DELISTED
Apollo Endosurgery, Inc.
APEN
$6.39M 0.13%
1,750,000
– –
XLO icon
61
Xilio Therapeutics
XLO
$58.5M
$6.07M 0.13%
148,478
– –
OM icon
62
Outset Medical
OM
$75.4M
$5.95M 0.12%
26,708
– –
CALC icon
63
CalciMedica
CALC
$11.3M
$5.76M 0.12%
377,265
– –
ANTX icon
64
AN2 Therapeutics
ANTX
$185M
$5.55M 0.11%
716,538
+132,402
+23% +$1.75M
OHPA
65
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
$4.9M 0.1%
500,000
– –
NYXH
66
Nyxoah
NYXH
$153M
$4.19M 0.09%
455,262
– –
ORTX
67
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.06M 0.08%
694,942
– –
ONCR
68
DELISTED
Oncorus, Inc.
ONCR
$3.97M 0.08%
3,148,977
– –
HOWL icon
69
Werewolf Therapeutics
HOWL
$18.1M
$3.92M 0.08%
958,125
– –
QSI icon
70
Quantum-Si Incorporated
QSI
$178M
$3.25M 0.07%
1,400,000
– –
KNTE
71
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.15M 0.07%
250,000
-735,568
-75% -$6.85M
AFIB
72
DELISTED
Acutus Medical Inc
AFIB
$2.97M 0.06%
2,648,386
– –
ANNX icon
73
Annexon
ANNX
$942M
$2.2M 0.05%
583,913
– –
DCTH icon
74
Delcath Systems
DCTH
$435M
$2M 0.04%
500,000
– –
ETNB
75
DELISTED
89bio
ETNB
$1.63M 0.03%
+506,100
New +$1.53M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2022 Portfolio in Review

As of Q2 2022, Deerfield Management held 140 positions worth $4.85B, up 8.4% from $4.47B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $1.26B in Q2 2022, closing 14 positions and reducing 12 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $22.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in HilleVax worth $28.6M.

  • Deerfield Management's largest Q2 2022 buy was HilleVax: 2,617,948 shares worth $28.6M.
  • Deerfield Management added most to Immunogen Inc in Q2 2022, an estimated $50.2M increase.
  • Deerfield Management's biggest Q2 2022 reduction was Kura Oncology, cutting an estimated $25.7M.
  • Deerfield Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $22.2M.
  • Deerfield Management's ten largest holdings make up 38% of its $4.85B portfolio in Q2 2022.
  • Deerfield Management opened 14 new positions and closed 14 in Q2 2022.
  • Deerfield Management's portfolio value rose 8.4% quarter-over-quarter to $4.85B.

Based on Deerfield Management's 13F filing for Q2 2022, filed 15 Aug 2022.